X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13210) 13210
Book Chapter (68) 68
Dissertation (55) 55
Publication (43) 43
Conference Proceeding (29) 29
Magazine Article (23) 23
Book / eBook (2) 2
Government Document (2) 2
Paper (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nsclc (9232) 9232
oncology (6359) 6359
humans (5954) 5954
female (3390) 3390
male (3306) 3306
lung cancer (3181) 3181
lung neoplasms - pathology (3092) 3092
chemotherapy (2966) 2966
lung cancer, non-small cell (2881) 2881
middle aged (2876) 2876
carcinoma, non-small-cell lung - pathology (2773) 2773
aged (2763) 2763
non-small cell lung cancer (2491) 2491
lung neoplasms - drug therapy (2470) 2470
carcinoma, non-small-cell lung - drug therapy (2438) 2438
cancer (2190) 2190
respiratory system (2070) 2070
lung neoplasms - genetics (1910) 1910
prognosis (1886) 1886
carcinoma, non-small-cell lung - genetics (1845) 1845
adult (1788) 1788
survival (1704) 1704
expression (1576) 1576
metastasis (1532) 1532
neoplasm staging (1347) 1347
mutation (1323) 1323
aged, 80 and over (1309) 1309
tumors (1207) 1207
gefitinib (1206) 1206
lung neoplasms - metabolism (1201) 1201
care and treatment (1153) 1153
lung neoplasms - mortality (1126) 1126
carcinoma, non-small-cell lung - metabolism (1124) 1124
cell line, tumor (1122) 1122
non-small cell lung carcinoma (1120) 1120
apoptosis (1114) 1114
treatment outcome (1107) 1107
carcinoma, non-small-cell lung - mortality (1078) 1078
adenocarcinoma (1053) 1053
analysis (1053) 1053
egfr (1051) 1051
carcinoma (1001) 1001
cell lung-cancer (972) 972
radiotherapy (939) 939
erlotinib (937) 937
therapy (924) 924
research (900) 900
open-label (894) 894
antineoplastic combined chemotherapy protocols - therapeutic use (875) 875
hematology, oncology and palliative medicine (871) 871
respiratory tract diseases (833) 833
animals (823) 823
pharmacology & pharmacy (819) 819
cisplatin (805) 805
lung cancer, small cell (797) 797
proliferation (787) 787
cell biology (774) 774
cancer therapies (767) 767
patients (758) 758
antineoplastic agents - therapeutic use (739) 739
immunohistochemistry (731) 731
immunotherapy (725) 725
docetaxel (706) 706
retrospective studies (698) 698
surgery (692) 692
original (687) 687
resistance (684) 684
survival analysis (670) 670
genetic aspects (669) 669
proteins (630) 630
survival rate (618) 618
biochemistry & molecular biology (613) 613
medicine, research & experimental (607) 607
growth (598) 598
radiology, nuclear medicine & medical imaging (590) 590
trial (579) 579
medical prognosis (578) 578
mutations (577) 577
pulmonary/respiratory (574) 574
gene expression (565) 565
epidermal growth factor (563) 563
medicine & public health (561) 561
biomarkers (557) 557
kinases (556) 556
growth-factor receptor (551) 551
non-small-cell lung cancer (548) 548
gene expression regulation, neoplastic (541) 541
acquired-resistance (540) 540
mice (533) 533
lung neoplasms - radiotherapy (521) 521
disease-free survival (520) 520
development and progression (516) 516
cell proliferation (514) 514
health aspects (514) 514
carboplatin (511) 511
review (508) 508
非小细胞肺癌 (492) 492
invasion (486) 486
lung neoplasms - therapy (486) 486
diagnosis (485) 485
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12241) 12241
Chinese (835) 835
German (141) 141
French (117) 117
Japanese (43) 43
Korean (37) 37
Polish (29) 29
Italian (25) 25
Czech (19) 19
Spanish (15) 15
Portuguese (11) 11
Turkish (7) 7
Russian (6) 6
Hungarian (4) 4
Norwegian (4) 4
Croatian (2) 2
Icelandic (2) 2
Persian (2) 2
Slovak (2) 2
Arabic (1) 1
Belarusian (1) 1
Dutch (1) 1
Indonesian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Radiotherapy and oncology, ISSN 0167-8140, 06/2016, Volume 119, Issue 3, pp. 480 - 486
Background and purpose Radiomics can quantify tumor phenotype characteristics non-invasively by applying advanced imaging feature algorithms. In this study we... 
Biomarkers | Pathological response | Quantitative imaging | NSCLC | Radiomics
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 7/2012, Volume 138, Issue 7, pp. 1113 - 1120
Fludarabine is an adenine nucleoside analogue that has significant activity in hematological malignancies and has shown promising activity in combination with... 
Nucleoside analogue | Fludarabine | Medicine & Public Health | Hematology | NSCLC | Radiochemotherapy in stage III NSCLC, locally advanced inoperable NSCLC | Oncology | Internal Medicine | Cancer Research | Concurrent fludarabine and radiotherapy | Radiotherapy, phase I study | Locally advanced inoperable NSCLC | Radiochemotherapy in stage III NSCLC | Phase I study | Radiotherapy | COMBINED CHEMOTHERAPY | CANCER | RADIATION-THERAPY | MURINE TUMOR | ONCOLOGY | HYPERFRACTIONATED RADIATION | locally advanced inoperable NSCLC | phase I study | WEEKLY GEMCITABINE | UNRESECTABLE STAGE-III | CELL | CONCURRENT CHEMORADIOTHERAPY | ARA-A | Carcinoma, Non-Small-Cell Lung - pathology | Radiotherapy Dosage | Carcinoma, Non-Small-Cell Lung - radiotherapy | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - radiotherapy | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Radiation-Sensitizing Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Medical research | Medical colleges | Care and treatment | Pneumonia | Bacterial pneumonia | Lung cancer | Radiation | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Antimitotic agents | Purines | Nuclear radiation | Analysis | Nucleosides | Medicine, Experimental | Tumors | Index Medicus | Original Paper
Journal Article
Oncotarget, ISSN 1949-2553, 12/2018, Volume 9, Issue 98, pp. 37157 - 37172
In this study we described that Signal Transducer and Activator of Transcription 1 (STAT1) is a key point regulator of PD-1 in tumour infiltrating lymphocytes... 
NSCLC | PDL1 | STAT1
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 09/2019, Volume 15, Issue 25, pp. 2905 - 2913
Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung... 
afatinib | 1ST-LINE TREATMENT | GEFITINIB | NSCLC | ONCOLOGY | SURVIVAL-DATA | SAFETY | sequential | NSCLC osimertinib | T790M MUTATION | T790M | OPEN-LABEL
Journal Article
International journal of molecular sciences, ISSN 1422-0067, 2019, Volume 20, Issue 1, p. 146
Journal Article
Asian Pacific journal of cancer prevention : APJCP, ISSN 1513-7368, 2015, Volume 16, Issue 7, pp. 2851 - 2855
Journal Article
Annals of oncology, ISSN 0923-7534, 2019, Volume 30, Issue 10, pp. 1653 - 1659
Background: In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on >= 50% of tumor cells, first-line treatment with the PD-1... 
pembrolizumab | ASSAY | NSCLC | VINORELBINE PLUS CISPLATIN | ONCOLOGY | PHASE-III | PD-L1 | BLOCKADE | CHEMOTHERAPY
Journal Article
Journal of thoracic oncology, ISSN 1556-0864, 2018, Volume 13, Issue 11, pp. 1771 - 1775
Checkpoint inhibitors augment the immune system’s natural surveillance mechanisms and have increasing applications in NSCLC. Immunosuppressive corticosteroids... 
immuno-oncology | NSCLC | nivolumab | corticosteroids | CELL LUNG-CANCER | ONCOLOGY | RESPIRATORY SYSTEM | DOCETAXEL
Journal Article